设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2021 年第 10 期 第 16 卷

慢性阻塞性肺疾病患者并发肺间质纤维化的血清学预测指标研究

Prediction of serum markers in patients with chronic obstructive pulmonary disease complicated with pulmonary fibrosis

作者:池菲1张新2王晓静3池毅2张媛媛1

英文作者:Chi Fei1 Zhang Xin2 Wang Xiaojing3 Chi Yi2 Zhang Yuanyuan1

单位:1河北省胸科医院急诊科,石家庄050000;2河北省胸科医院呼吸科,石家庄050000;3河北省胸科医院感染科,石家庄050000

英文单位:1Department of Emergency Hebei Chest Hospital Shijiazhuang 050000 China; 2Department of Respiratory Hebei Chest Hospital Shijiazhuang 050000 China; 3Department of Infection Hebei Chest Hospital Shijiazhuang 050000 China

关键词:慢性阻塞性肺疾病;肺间质纤维化;转化生长因子β1;碱性成纤维细胞生长因子;血管紧张素Ⅱ

英文关键词:Chronicobstructivepulmonarydisease;Pulmonaryfibrosis;Transforminggrowthfactor-β1;Basicfibroblastgrowthfactor;Angiotensin 

  • 摘要:
  • 目的  分析血清转化生长因子β1TGF-β1)、碱性成纤维细胞生长因子(bFGF)、血管紧张素Ⅱ(AngⅡ)水平对慢性阻塞性肺疾病(COPD)患者并发肺间质纤维化的预测价值。方法 选取河北省胸科医院20176月至20195月收治的128COPD患者(COPD组)和120例健康志愿者(健康组)。比较2组血清TGF-β1bFGFAngⅡ水平;随访1年,计算COPD组肺间质纤维化的发生率,对比发生与未发生肺间质纤维化的COPD患者(并发组与未并发组)的肺功能;分析血清TGF-β1bFGFAngⅡ水平与COPD并发肺间质纤维化的关系及对其预测效能。结果 COPD组随访期间3例失访、2例确诊为肺癌脱落。COPD组血清TGF-β1bFGFAngⅡ水平均高于健康组[(42±10)μg/L比(28±5)μg/L、(24±4ng/L比(17±4ng/L、(30±5ng/L比(21±4ng/L](均P0.001)。COPD组肺间质纤维化发生率为25.2%31/123),并发组第1秒用力呼气容积(FEV1)、FEV1与用力肺活量比值、二氧化碳弥散量均低于未并发组,功能残气容积/肺总量高于未并发组(均P0.001),年龄、烟龄、COPD病程、急性加重期、肺功能34级、烟雾/粉尘工作环境、血清TGF-β1bFGFAngⅡ水平、急性加重发作频率均是COPD并发肺间质纤维化的危险因素,治疗依从是其保护因素(均P0.05);血清TGF-β1bFGFAngⅡ联合检测预测COPD并发肺间质纤维化的敏感度和曲线下面积均高于单独检测(均P0.05)。结论 血清TGF-β1bFGFAngⅡ水平升高的COPD患者并发肺间质纤维化风险高,3项指标联合可预测COPD患者肺间质纤维化的发生情况。

  • Objective To analyze the predictive value of serum transforming growth factor-β1 (TGF-β1), basic fibroblast growth factor (bFGF) and angiotensin (Ang) levels in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary fibrosis. Methods From June 2017 to May 2019, 128 COPD patients admitted to Hebei Chest Hospital (COPD group) and 120 healthy volunteers undergoing physical examination(healthy group) were selected. The serum levels of TGF-β1, bFGF and Ang were compared between the two groups. After 1-year follow-up, the incidence of pulmonary fibrosis in COPD group was calculated; the pulmonary function were compared between patients who did and did not develop pulmonary fibrosis. The relationships between serum TGF -β1, bFGF, Ang levels and COPD complicated with pulmonary fibrosis  and their predictive efficacy were analyzed. Results In COPD group, 3 cases were lost to follow-up and 2 cases were drop out as lung cancer. The levels of TGF -β1, bFGF and Ang in COPD group were higher than those in healthy group[(42±10)μg/L vs 28±5)μg/L,24±4ng/L vs 17±4ng/L,30±5ng/L vs 21±4ng/L](all P0.001. The incidence of pulmonary fibrosis in COPD group was 25.2%31/123, and the forced expiratory volume in the first second (FEV1), ratio of FEV1 to forced vital capacity, diffusion capacity of carbon dioxide in complicated group were lowerer than those in non complicated group, the functional residual volume/total lung capacity in complicated group was higher than that in non complicated group (all P0.001). Age, smoking age, duration of COPD, acute exacerbation, grade 3-4 pulmonary function, smoke/dust working environment, serum levels of TGF-β1, bFGF, Ang and frequency of acute exacerbation were all risk factors of COPD complicated with pulmonary fibrosis, and treatment compliance was a protective factor (all P0.05). The sensitivity and the area under the curve of combined detection of serum TGF-β1, bFGF and Ang in predicting COPD complicated with pulmonary fibrosis were higher than those of single detection (all P0.05). Conclusions  COPD patients with high serum levels of TGF-β1, bFGF and Ang have high risk to complicate pulmonary fibrosis. The combination of the three factors can predict the occurrence of pulmonary fibrosis.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map